Quantum-Si Honored with Frost & Sullivan’s 2024 Technology Innovation Leadership Award for Next-Generation Protein Sequencing™

Audio By Carbonatix

BRANFORD, Conn.--(BUSINESS WIRE)--Nov 13, 2024--

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it has been awarded Frost & Sullivan’s prestigious 2024 Technology Innovation Leadership Award in North America. This award recognizes QSI’s groundbreaking work in developing the Platinum ® instrument, the first benchtop sequencer capable of providing single-molecule resolution at the amino acid level, opening new frontiers for proteomic research.

Frost & Sullivan’s independent team of experts selected QSI for this honor based on the company’s pioneering technology and commitment to advancing proteomics. The Platinum instrument addresses a crucial need for high-resolution protein sequencing by enabling deep insights into protein structure and function within a compact, accessible, and cost-effective instrument. This technology brings single-molecule protein sequencing into labs of all sizes, transforming the way researchers can explore protein variants, modifications, and interactions without the complex workflows and high costs traditionally associated with protein analysis.

“Receiving Frost & Sullivan’s 2024 Technology Innovation Leadership Award is a testament to our team’s dedication to advancing the proteomics field,” said Jeff Hawkins, CEO of Quantum-Si. “The Platinum instrument enables researchers to achieve unprecedented insights at the amino acid level, empowering both core and non-core labs to drive scientific discovery faster and more efficiently.”

Quantum-Si’s Platinum instrument integrates unique engineering solutions, including proprietary image sensors that enable single-molecule detection and precision sequencing. It captures fluorescence signals from each amino acid binding event, providing an end-to-end solution for direct protein sequencing with high accuracy. The device’s affordability and compact design allow more labs to bring proteomic research in-house, reducing dependence on costly external resources and enhancing productivity.

Frost & Sullivan’s analysis highlights Quantum-Si’s strong commitment to innovation and operational excellence, recognizing its extensive intellectual property portfolio with over 1,000 issued and pending patents. The award highlights QSI’s strategic approach to advancing technology that addresses the evolving needs of the proteomics field.

For more information on Quantum-Si’s technology and research applications, please visit The Protein Sequencing Company™ | Quantum-Si

About Quantum-Si Incorporated

Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum ® instrument enables Next-Generation Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.

View source version on businesswire.com:https://www.businesswire.com/news/home/20241113522948/en/

CONTACT: Investor Contact

Doug Farrell, VP, Investor Relations

[email protected]

Media Contact

Katherine Atkinson, SVP, Commercial Marketing

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CONNECTICUT

INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL HARDWARE ONCOLOGY HEALTH TECHNOLOGY

SOURCE: Quantum-Si Incorporated

Copyright Business Wire 2024.

PUB: 11/13/2024 06:00 AM/DISC: 11/13/2024 06:00 AM

http://www.businesswire.com/news/home/20241113522948/en